文献速递胃肠外科围术期管理与 ERAS

美国机器人辅助与腹腔镜减重手术的国家趋势与结局

National trends and outcomes of robotic and laparoscopic bariatric surgery in the United States.
PubMed 文献 · Surgery · 2026-08-31

该研究基于2016-2022年美国再入院数据库,比较机器人辅助与腹腔镜代谢减重手术的短期结局和资源利用。结论认为机器人手术虽资源利用更高,但未显示短期临床优势。

要点

  • 腹腔镜减重手术与更低的主要不良事件、感染和呼吸并发症风险相关。
  • 机器人减重手术费用更高,且30天再入院风险更高。
  • 需前瞻性研究评估机器人减重手术的临床与经济价值。

核心结论

  • 在全国代表性分析中,机器人代谢减重手术相比腹腔镜手术未显示短期临床优势,且资源利用更高。

研究设计与样本

  • 研究从2016-2022年美国再入院数据库提取所有≥18岁成人择期初次机器人或腹腔镜代谢减重手术住院记录。
  • 纳入术式包括可调节胃束带、胆胰分流/十二指肠转位、Roux-en-Y胃旁路术和袖状胃切除术。
  • 采用多变量模型评估手术方式与结局的关联,并用限制性立方样条分析医院层面手术量与费用的关系。

主要发现

  • 共估计1,136,027例患者,其中腹腔镜组938,999例(82.6%)。
  • 腹腔镜组女性比例较低,Elixhauser合并症指数较低。
  • 风险调整后,腹腔镜手术与主要不良事件风险降低相关(aOR 0.58,95%CI 0.46-0.75)。
  • 腹腔镜手术与感染并发症风险降低相关(aOR 0.28,95%CI 0.18-0.42)。
  • 腹腔镜手术与呼吸系统并发症风险降低相关(aOR 0.81,95%CI 0.71-0.92)。

临床怎么用

  • 在缺乏短期临床优势证据的情况下,机器人减重手术的推广应权衡其更高的资源利用。
  • 临床决策可参考腹腔镜手术在主要不良事件、感染、呼吸并发症、费用和再入院方面的相对优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While robotic-assisted metabolic and bariatric surgery has experienced rapid national adoption, data on postoperative outcomes relative to laparoscopic approaches remain mixed. The present study used a nationally representative cohort to characterize outcomes and resource utilization across laparoscopic and robotic metabolic and bariatric surgery. METHODS: All elective adult (≥18 years) hospitalizations for primary robotic or laparoscopic metabolic and bariatric surgery were extracted from the 2016-2022 National Readmissions Database. Eligible procedures included adjustable gastric banding, biliopancreatic diversion/duodenal switch, Roux-en-Y gastric bypass, and sleeve gastrectomy. Multivariable models were developed to assess the association of procedure approach with outcomes of interest. Restricted cubic spline analysis examined the volume-cost relationship at the hospital level. RESULTS: Of an estimated 1,136,027 patients, 938,999 (82.6%) comprised the laparoscopic cohort. Compared with robotic metabolic and bariatric surgery, the laparoscopic cohort was less commonly female and demonstrated lower Elixhauser Comorbidity Indices. Following risk adjustment, laparoscopic intervention was associated with reduced odds of major adverse events (adjusted odds ratio, 0.58; 95% confidence interval, 0.46-0.75), infectious complications (adjusted odds ratio, 0.28; 95% confidence interval, 0.18-0.42), and respiratory complications (adjusted odds ratio, 0.81; 95% confidence interval, 0.71-0.92). The laparoscopic approach was additionally associated with lower costs (β = -4.1; 95% confidence interval, -4.6 to -3.7) and reduced odds of 30-day readmission (adjusted odds ratio, 0.85; 95% confidence interval, 0.81-0.90), compared with robotic. CONCLUSION: In this nationally representative analysis, robotic metabolic and bariatric surgery was not associated with a short-term clinical advantage over laparoscopic approaches, despite higher resource utilization. These findings underscore the need for rigorous prospective evaluation of the clinical and economic value of robotic metabolic and bariatric surgery prior to its continued expansion.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Tran D, Ali K, Wong J, et al. National trends and outcomes of robotic and laparoscopic bariatric surgery in the United States. Surgery. 2026. PMID: 42805017. doi:10.1016/j.surg.2026.110574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。